JP2022531685A5 - - Google Patents
Info
- Publication number
- JP2022531685A5 JP2022531685A5 JP2021565869A JP2021565869A JP2022531685A5 JP 2022531685 A5 JP2022531685 A5 JP 2022531685A5 JP 2021565869 A JP2021565869 A JP 2021565869A JP 2021565869 A JP2021565869 A JP 2021565869A JP 2022531685 A5 JP2022531685 A5 JP 2022531685A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- weight
- composition according
- methylnaltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844613P | 2019-05-07 | 2019-05-07 | |
| US62/844,613 | 2019-05-07 | ||
| US202063010528P | 2020-04-15 | 2020-04-15 | |
| US63/010,528 | 2020-04-15 | ||
| PCT/EP2020/062794 WO2020225395A1 (en) | 2019-05-07 | 2020-05-07 | Liquid oral dosage formulations of methylnaltrexone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531685A JP2022531685A (ja) | 2022-07-08 |
| JP2022531685A5 true JP2022531685A5 (enExample) | 2023-05-15 |
| JP7692366B2 JP7692366B2 (ja) | 2025-06-13 |
Family
ID=70802839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565869A Active JP7692366B2 (ja) | 2019-05-07 | 2020-05-07 | メチルナルトレキソンの液体経口投与製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220096461A1 (enExample) |
| EP (1) | EP3965731A1 (enExample) |
| JP (1) | JP7692366B2 (enExample) |
| CN (1) | CN113747882A (enExample) |
| AU (1) | AU2020268767B8 (enExample) |
| BR (1) | BR112021022194A2 (enExample) |
| CA (1) | CA3137488C (enExample) |
| MX (1) | MX2021013488A (enExample) |
| WO (1) | WO2020225395A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
| AU2022248850A1 (en) * | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| WO2025177181A1 (en) * | 2024-02-19 | 2025-08-28 | Nanoprime Labs Corp | Self-assembling microemulsions carrying nutraceuticals and methods for use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4816259A (en) | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| CN1688294A (zh) | 2002-10-01 | 2005-10-26 | 旗帜药物胶囊公司 | 用于制备软胶囊壁的肠溶组合物 |
| MXPA05010821A (es) | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico. |
| JP2006522817A (ja) | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI605814B (zh) * | 2010-03-11 | 2017-11-21 | 惠氏有限責任公司 | 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽 |
| JP6397813B2 (ja) | 2012-05-02 | 2018-09-26 | キャプシュゲル・ベルジウム・エヌ・ヴィ | ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液 |
| US10485798B2 (en) * | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| EP3206491B1 (en) * | 2014-10-17 | 2019-11-27 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
-
2020
- 2020-05-07 WO PCT/EP2020/062794 patent/WO2020225395A1/en not_active Ceased
- 2020-05-07 BR BR112021022194A patent/BR112021022194A2/pt unknown
- 2020-05-07 CA CA3137488A patent/CA3137488C/en active Active
- 2020-05-07 EP EP20727590.0A patent/EP3965731A1/en active Pending
- 2020-05-07 MX MX2021013488A patent/MX2021013488A/es unknown
- 2020-05-07 JP JP2021565869A patent/JP7692366B2/ja active Active
- 2020-05-07 CN CN202080033965.4A patent/CN113747882A/zh active Pending
- 2020-05-07 AU AU2020268767A patent/AU2020268767B8/en not_active Expired - Fee Related
-
2021
- 2021-10-06 US US17/495,413 patent/US20220096461A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11395811B2 (en) | Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof | |
| JP2021523909A (ja) | 医薬製剤 | |
| KR20180120683A (ko) | 생물학적으로 활성인 칸나비디올 유사체 | |
| WO2010019953A1 (en) | High concentration local anesthetic formulations for treating non-neuropathic pain | |
| US12558321B2 (en) | Pharmaceutical formulation | |
| JP7781998B2 (ja) | Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物 | |
| US12303599B2 (en) | Self-emulsifying cannabidiol formulations | |
| TW201521719A (zh) | 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法 | |
| EP2637655B1 (en) | Pharmaceutical composition of taxoids | |
| RS56324B1 (sr) | Sublingvalna primena statina | |
| JP2015511213A (ja) | 薬物送達技術 | |
| KR102771577B1 (ko) | 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형 | |
| JP2022531685A (ja) | メチルナルトレキソンの液体経口投与製剤 | |
| GB2469754A (en) | Sub-lingual drug delivery system using a neutral oil | |
| WO2016179137A1 (en) | Compositions and methods for delivery of polyunsaturated fatty acid derivatives and analogs | |
| US9593120B2 (en) | Paralytic shellfish poison | |
| EP3727454A1 (en) | Oral pharmaceutical composition of an nk-1 antagonist | |
| CN110402142A (zh) | 含局麻药的酸性乳液组合物 | |
| RU2006106173A (ru) | Усовершенствованная система доставки лекарств | |
| AU2922800A (en) | Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter | |
| KR20250156775A (ko) | 크레아틴 에스테르의 투여에 적합한 조성물 | |
| US20260069614A1 (en) | Novel parenteral formulations of cannabidiol | |
| WO2022271537A1 (en) | Compositions and methods relating to injectable microemulsions | |
| AU2024318251A1 (en) | Oral formulations of cannabinoids | |
| RU2025107453A (ru) | Пероральные лекарственные формы для лечения расстройств печени и способы их получения |